PMID- 37582197
OWN - NLM
STAT- Publisher
LR  - 20230815
IS  - 2378-8763 (Electronic)
IS  - 2378-8763 (Linking)
DP  - 2023 Aug 11
TI  - Sex Differences in the Safety and Subjective Effects of Two Oral 
      Delta9-Tetrahydrocannabinol-Containing Cannabis Products over Multiple Doses Among 
      Healthy Adults.
LID - 10.1089/can.2022.0340 [doi]
AB  - Introduction: A growing number of females report consuming cannabis products. 
      There is a paucity of data on sex differences in safety and subjective effects 
      after repeated use of varying oral doses of Delta9-tetrahydrocannabinol (THC; the 
      primary psychoactive constituent of cannabis). Materials and Methods: Data were 
      from two randomized, double-blind, placebo-controlled, multiple-dose, 
      between-subject trials of two THC-containing oral cannabis products. Healthy 
      adults received placebo, low-dose THC ( approximately 2.5 or  approximately 5 mg per dose), or high-dose THC 
      ( approximately 7.5 or  approximately 10 mg per dose) twice daily for 7 days. There were 38 males (8 placebo, 
      17 low-dose THC, 13 high-dose THC) and 46 females (8 placebo, 17 low-dose THC, 21 
      high-dose THC). Analyses compared adverse events (AEs) and subjective effects 
      between males and females, by THC dose. Results: In the placebo and low-dose THC 
      groups, there were no sex differences in the relative rate of AEs. In the 
      high-dose THC group, females versus males reported 3.08 (95% confidence interval 
      [CI]=1.31-8.33) times as many AEs. There were no significant interactions of 
      sexxlow-dose THC group for any subjective effect. In the high-dose THC group, 
      females versus males reported greater "relaxed" ratings (b=15.14, 95% 
      CI=1.44-28.84, p=0.027), whereas in the placebo group, males versus females 
      reported greater ratings of "liking the effect" (b=-30.01, 95% CI=2.77-57.26, 
      p=0.028). Although analyses were underpowered to assess the sexxTHC dosexday 
      interaction, the initial sex disparity in AEs and some subjective effects in the 
      high-dose THC group appeared to shrink after the first day. Conclusions: In this 
      exploratory analysis, sex differences in some responses to oral THC were nuanced. 
      Females appeared more sensitive than males to AEs and some subjective effects at 
      higher but not lower doses. Males reported higher ratings than females on some 
      subjective effects in response to placebo. Initial sex differences in response to 
      higher doses of oral THC tended to diminish over 7 days of dosing. If replicated, 
      findings could help inform sex-specific dosing strategies of medical cannabis 
      products and could help educate medical cannabis patients on any temporality of 
      effects.
FAU - MacNair, Laura
AU  - MacNair L
AD  - Canopy Growth Corporation, Smiths Falls, Ontario, Canada.
FAU - Eglit, Graham M L
AU  - Eglit GML
AD  - Canopy Growth Corporation, Smiths Falls, Ontario, Canada.
FAU - Mosesova, Irina
AU  - Mosesova I
AD  - Canopy Growth Corporation, Smiths Falls, Ontario, Canada.
FAU - Bonn-Miller, Marcel O
AU  - Bonn-Miller MO
AUID- ORCID: 0000-0001-5088-5386
AD  - Canopy Growth Corporation, Smiths Falls, Ontario, Canada.
FAU - Peters, Erica N
AU  - Peters EN
AUID- ORCID: 0000-0002-5563-9819
AD  - Canopy Growth Corporation, Smiths Falls, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20230811
PL  - United States
TA  - Cannabis Cannabinoid Res
JT  - Cannabis and cannabinoid research
JID - 101684827
SB  - IM
OTO - NOTNLM
OT  - cannabis
OT  - safety
OT  - sex differences
OT  - subjective effects
OT  - Delta9-tetrahydrocannabinol
EDAT- 2023/08/15 18:42
MHDA- 2023/08/15 18:42
CRDT- 2023/08/15 14:33
PHST- 2023/08/15 18:42 [medline]
PHST- 2023/08/15 18:42 [pubmed]
PHST- 2023/08/15 14:33 [entrez]
AID - 10.1089/can.2022.0340 [doi]
PST - aheadofprint
SO  - Cannabis Cannabinoid Res. 2023 Aug 11. doi: 10.1089/can.2022.0340.